Salix Xifaxan data should be positive, says JMP Securities JMP Securities expects upcoming data for Salix's Xifaxan for the retreatment of diarrhea-predominant irritable bowel syndrome to be significantly positive. The firm expects the stock to rise significantly on the news. It reiterates a $150 price target and Outperform rating on the shares.
News For SLXP From The Last 14 Days
Check below for free stories on SLXP the last two weeks.